Marina Biotech and Mirna Therapeutics Amend License Agreement for the Development of microRNA-based Therapeutics

Marina Biotech Announces Organizational Changes

Marina Biotech Strengthens the Intellectual Property Estate for SMARTICLES® Nucleic Acid Delivery Technology

Marina Biotech Strengthens the Intellectual Property Estate for the Transkingdom RNA Interference Nucleic Acid Delivery Technology

Marina Biotech Achieves Broad Patent Coverage for DiLA2 Nucleic Acid Delivery Technology in U.S., Europe and Japan

Marina Biotech Announces $6 MM Convertible Preferred Stock Financing and Conversion to Common Stock of the Company’s Promissory Note

Marina Biotech Continues to Build Worldwide Patent Protection for its SMARTICLES® Nucleic Acid Delivery Technology

Marina Biotech to use its RNAi, Antisense and microRNA Therapeutics Platform to Develop Drugs for Rare Diseases

Rosetta Genomics and Marina Biotech Establish Strategic Alliance to Jointly Develop microRNA-based Diagnostics and Therapeutics for Rare Diseases

Marina Biotech Presents Clinical Data Demonstrating Delivery of both Single and Double-Stranded Nucleic Acids to Tumors